the aid library

LIST OPTIONS

Filter

5120

Download (256)

View PDF (276)

A Cross-Sectional Study of Disclosure of HIV Status to Children and Adolescents in Western Kenya

R. C. Vreeman; M. L. Scanlon; A. Mwangi; et al. PLOS One (2014) CC

PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e86616

Download (233)

View PDF (264)

Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm (28 October 2021), updated 15 March 2022

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below. Th... more

External Link

The successful COVID-19 vaccine rollout in Chile: Factors and challenges

Castillo C., Villalobos Dintrans P. et al (2021) C2

The aim of this article is to identify the elements behind the country’s successful COVID-19 rollout as well as lessons and chal lenges derived from this process. The analysis is relevant to many countries today—as they keep searching for strategies to cope with the second year of the COVID-19 p... more

Download (460)

View PDF (354)

Preparedness and Response for a Nuclear or Radiological Emergency Combined with Other Incidents or Emergencies

International Atomic Energy Agency IAEA, WHO; OCHA; ET al. (2020) C_WHO

IAEA Safety Standards for protecting people and the environment

External Link

A double dose of inequality; Pharma companies and the Covid-19 vaccines crisis

Amnesty International (2022) C2

22 Sept. 2021 The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisi... more

Download (440)

View PDF (590)

Essential List for screening, monitoring and treatment for diabetic retinopathy

International Agency for Prevention of Blindness IAPB (2018) C1

3rd edition April 2018 - draft version This Essential List for Diabetic Retinopathy contains recommendations for a range of essential itemsrequired at community / primary level (for screening); at secondary and tertiary levels (for treatment and follow up). It also contains recommendations for i... more

Download (353)

View PDF (498)

Investment guidelines for youth in agrifood systems in Africa

Food and Agriculture Organization of the United Nations FAO and African Union AU (2022) C1

The Investment guidelines for youth in agrifood systems in Africa, developed jointly by FAO and the African Union Commission (AUC) through a multi-stakeholder and participatory process, highlight the importance of youth as change agents and key stakeholders contributing to sustainable agrifood syste... more

Download (1209)

View PDF (1002)

Tips on Nutrition Interventions for the Humanitarian Response Plan

Nutrition Cluster (2016) CC

External Link

Keeping community health workers in Uganda motivated: key challenges, facilitators, and preferred program inputs

Bruniea, A.; P. Wamala-Mucheri, C. Otterness, et al. (2014) CC

Glob Health Sci Pract February 1, 2014 vol. 2 no. 1 p. 103-116

External Link

Monkeypox outbreaks outside endemic regions: scientific and social priorities
recommended

A. Zumla; Valdoleiros, S. R.; Haider, N.; et al. The Lancet (2022) CC

As the world recovers from the shock of the COVID-19 pandemic and reflects on lessons learnt from failure of global public health systems to contain the global outbreak of SARS-CoV-2, new infectious disease threats, caused by movement of people globally, remain omnipresent, and repeated calls for mo... more

Download (853)

View PDF (1319)

Nepal Global Health Initiative Strategy

Nepal GHI Strategy (2010) C1

Download (228)

View PDF (336)

Practice Education in Nursing

Registered Nurses’ Association of Ontario (RNAO) (2016) CC

The purpose of this Guideline is to provide evidence-based recommendations that promote and sustain the undergraduate nursing student’s application of knowledge to practice in a variety of clinical learning environments. The Guideline explores the relationships among and between students and nursi... more

Download (504)

View PDF (522)

Comprehensive Evaluation of the Community Health Program in Rwanda (FINAL REPORT)

Centre for Maternal and Newborn Health (CMNH), from the Liverpool School of Tropical Medicine (LSTM) (2016) C2

The objective of the evaluation is to understand whether the CHW program has achieved its intended objectives, thus contributing to the overarching objectives defined in the HSSP III of improving the health status of the population by “Ensuring universal accessibility of quality health services fo... more

Download (151)

View PDF (172)

Epidemiology and Challenges of Managing COPD in sub-Saharan Africa

Magitta, N.F.; Sciences, A. Acta Scientific Medical Sciences (2018) CC2

There is paucity of data on the burden and specific drivers operative in the pathogenesis of chronic obstructive pulmonary disease (COPD) in the African setting and populations. Lack of awareness and inadequate knowledge on the aetio-pathogenesis of the disease together with inadequate capacity for ... more

Download (158)

View PDF (427)

The Global Burden of Disease Study at 30 years

Murray, C.J.L. nature medicine (2022) CC

The Global Burden of Disease Study (GBD) began 30 years ago with the goal of providing timely, valid and relevant assessments of critical health outcomes. Over this period, the GBD has become progressively more granular. The latest iteration provides assessments of thousands of outcomes for diseases... more

Download (327)

View PDF (350)

Mental Health in the times of COVID-19 Pandemic

National Institute of Mental Health & Neurosciences, Bengaluru India; Dept. of Psychiatry (2020) CC

Guidance for General Medical and Specialised Mental Health Care Settings

Download (272)

View PDF (378)

WHO global report on trends in prevalence of tobacco use 2000-2025

World Health Organization WHO (2021) C_WHO

Progress in reducing tobacco use is a key indicator for measuring countries’ efforts to implement the WHO Framework Convention on Tobacco Control – target 3.a under the Sustainable Development Goals agenda. Countries have adopted this indicator to report progress also towards the tobacco reducti... more

Download (262)

View PDF (533)

Reflection on inclusive health services in northwest Syria (NWS)

Islamic Relief (2022) CC

After a decade of crisis, Syria remains one of the world’s most complex humanitarian crises. Continued hostilities, new and protracted displacement, increased returns and the sustained destruction of communities have impacted Syrians’ lives and futures in a devastating way. The 2021 Humanitarian... more

Download (484)

View PDF (340)

National Guidelines for Integrated Diseases Surveillance and Response Uganda

World Health Organization WHO, Regional Office of Africa; Ministry of Health Uganda (2021) C_WHO

3rd edition. In 2001, Uganda adapted the Integrated Disease Surveillance and Response (IDSR) developed by World Health Organization (WHO) for member states in African region. The Ministry of Health has been implementing the IDSR strategy since then with success across the country. This strategy prov... more

Download (439)

View PDF (661)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Monkeypox outbreaks outside endemic regions: scientific and social priorities recommended

Monkeypox outbreaks outside endemic regions: scientific and social priorities
recommended